Do You Take Sermorelin 7 Days a Week? Dosing Guide

Last Updated: May 25, 2026

Do You Take Sermorelin 7 Days a Week or Follow a Cycle?

The question of whether do you take sermorelin 7 days a week or follow a structured cycle is one of the most common points of confusion for patients starting peptide therapy. At Ascend Vitality, we work with patients navigating exactly this decision, and the short answer is: most prescribers do not recommend daily dosing every single day of the week, at least not indefinitely. The standard clinical approach involves cycling, and there are solid physiological reasons for that. Below, we’ll explain the science behind dosing frequency, walk through what a typical sermorelin dosing schedule looks like, and cover what your prescriber is weighing when they choose your protocol.

Sermorelin Acetate is a synthetic analog of Growth Hormone Releasing Hormone (GHRH), the natural signal your hypothalamus sends to the pituitary gland to trigger human growth hormone (HGH) production. Unlike synthetic HGH, sermorelin works by stimulating your own pituitary gland rather than replacing its function. That distinction matters enormously for how you dose it.

What Is Sermorelin Acetate and How Does It Work?

Sermorelin Acetate is a prescription-only compounded medication that mimics the body’s natural GHRH signal, prompting the pituitary gland to produce and release growth hormone in a pulsatile, physiologically appropriate pattern. This is the core reason sermorelin is considered a more nuanced option than exogenous HGH: it works with the endocrine system rather than overriding it.

After subcutaneous injection, sermorelin is absorbed rapidly and binds to GHRH receptors on the pituitary gland. This triggers a release of growth hormone, which then stimulates the liver to produce Insulin-like Growth Factor 1 (IGF-1). IGF-1 levels are the primary downstream marker clinicians track to gauge whether a sermorelin protocol is working. The entire cascade is self-limiting, meaning the body’s natural feedback mechanisms remain intact, which is a meaningful safety advantage over exogenous hormone replacement therapy (HRT).

Why Dosing Frequency Matters for Pituitary Health

Here’s the part most guides skip over: the pituitary gland is not designed to receive a continuous, unvarying hormonal signal. Natural GHRH release is pulsatile, meaning it surges and recedes throughout the day, with the largest pulse typically occurring during deep sleep. When you administer sermorelin, you’re mimicking that pulse. Administer it too frequently without breaks, and you risk desensitizing the GHRH receptors on the pituitary, which reduces the effectiveness of each dose over time. This is the clinical rationale behind cycling protocols, and it’s why the question of do you take sermorelin 7 days a week doesn’t have a simple yes-or-no answer.

Sermorelin Dosing Schedule: What Prescribers Typically Recommend

Most prescribers approach sermorelin dosing schedules conservatively and adjust based on individual patient response. There is no universal protocol, but there are common patterns that reflect both clinical experience and the pharmacology of the peptide.

The most widely used starting approach involves subcutaneous injections administered before bedtime, timed to align with the body’s natural nocturnal growth hormone pulse. Dosing is typically prescribed as a compounded medication measured in micrograms (mcg), and the concentration of the vial determines how many milliliters (mL) or units you draw.

Sermorelin Dosage Chart: Reading mcg, mL, and Units

Understanding your prescription requires reading three values correctly: the dose in micrograms (mcg), the vial concentration, and the resulting volume in mL or units on an insulin syringe. A common source of error is confusing units on an insulin syringe with micrograms. They are not the same thing.

Here is a reference chart for common sermorelin concentrations:

Vial Concentration	Prescribed Dose	Volume to Draw	Insulin Syringe Units
2 mg/mL (2,000 mcg/mL)	200 mcg	0.10 mL	10 units
2 mg/mL (2,000 mcg/mL)	300 mcg	0.15 mL	15 units
5 mg/mL (5,000 mcg/mL)	200 mcg	0.04 mL	4 units
5 mg/mL (5,000 mcg/mL)	500 mcg	0.10 mL	10 units

Always confirm your vial concentration with your prescriber or compounding pharmacy before drawing any dose. Patient-specific dosing means the chart above is illustrative, not prescriptive.

Patient-Specific Dosing: Why One Size Does Not Fit All

A common mistake is expecting a fixed protocol that applies to every patient. Prescribers adjust sermorelin dosing based on body weight, baseline IGF-1 levels, age, treatment goals (fat metabolism, muscle recovery, weight management), and tolerance to the medication. Older patients often have more significantly suppressed pituitary function and may require longer treatment periods before IGF-1 levels shift meaningfully. Patients focused on body composition outcomes may be dosed differently than those pursuing general endocrine health or recovery support.

Sermorelin 5 Days On 2 Days Off: The Cycling Protocol Explained

The sermorelin 5 days on 2 days off protocol is the most commonly prescribed cycling approach, and it’s the standard most clinicians default to at the start of therapy. The two days off are typically the weekend, though the specific days are less important than maintaining the rhythm consistently.

The logic is straightforward: two days without stimulation gives GHRH receptors time to reset and maintain their sensitivity to the peptide. Patients who skip the cycling phase and dose seven days continuously often report diminishing returns over weeks, which is a practical signal that receptor desensitization is occurring.

Scientific Rationale: Cycling vs. Continuous Daily Use

The physiological case for cycling comes down to receptor dynamics. GHRH receptors on the pituitary gland are subject to downregulation with prolonged, uninterrupted stimulation. This is a well-documented phenomenon in endocrine pharmacology: continuous agonist exposure tends to reduce receptor density and sensitivity over time, a process called desensitization or tachyphylaxis.

According to National Institutes of Health research on GHRH receptor regulation, pulsatile GHRH signaling is essential for maintaining pituitary responsiveness, and disrupting that pulsatility through continuous exposure can blunt the growth hormone response. The 5-days-on, 2-days-off model attempts to preserve that pulsatility at the weekly level, even if daily injections are more frequent than the body’s natural pattern.

Continuous daily dosing is not inherently dangerous, and some protocols do use it, particularly for patients with significantly suppressed IGF-1 levels under close medical supervision. But for most patients starting therapy, cycling is the safer and more sustainable default.

Transitioning From a 5-Day to a 7-Day Protocol

Some prescribers do move patients to a 7-day protocol after an initial cycling phase, typically after confirming IGF-1 response through bloodwork and establishing that the patient tolerates the medication well. This transition is not automatic and should not be self-initiated.

The general transition pathway looks like this:

1. Start with 5 days on, 2 days off for the first 3 to 6 months
2. Monitor IGF-1 levels at 90-day intervals
3. If IGF-1 response is stable and tolerance is confirmed, the prescriber may adjust to daily dosing
4. Continue monitoring every 90 days on the new protocol
5. If IGF-1 plateaus or declines, return to the cycling protocol

The practical point: do you take sermorelin 7 days a week long-term depends entirely on your bloodwork response and your prescriber’s clinical judgment. It is not a decision made by the patient unilaterally.

Sermorelin Receptor Desensitization: The Real Reason You May Not Take It Every Day

Receptor desensitization is the central clinical argument against unrestricted daily sermorelin use, and it deserves more than a passing mention. Most articles on this topic state the conclusion, cycle your doses, without explaining the underlying biology in enough detail to be genuinely useful. This section fills that gap.

How GHRH Receptor Downregulation Actually Works

The pituitary gland contains specialized cells called somatotrophs, which are responsible for synthesizing and secreting growth hormone. On the surface of each somatotroph are GHRH receptors, G-protein coupled receptors (GPCRs) that, when activated by GHRH or a GHRH analog like sermorelin, trigger a signaling cascade that ultimately results in GH release.

Like all GPCRs, GHRH receptors are subject to a regulatory process called homologous desensitization. The mechanism works in two stages:

1. Short-term desensitization (minutes to hours): Repeated or sustained agonist binding causes the receptor to be phosphorylated by G-protein coupled receptor kinases (GRKs). This phosphorylation recruits a protein called beta-arrestin, which physically uncouples the receptor from its downstream signaling proteins. The receptor is still present on the cell surface but is functionally silenced, it can bind sermorelin but no longer triggers a meaningful GH pulse.
2. Long-term downregulation (days to weeks): With prolonged continuous stimulation, the desensitized receptors are internalized into the cell via endocytosis. Once internalized, receptors are either recycled back to the surface (resensitization) or degraded. When the rate of degradation exceeds the rate of new receptor synthesis, total receptor density on the somatotroph surface falls. Fewer available receptors means a smaller GH pulse per injection, regardless of dose.

This two-stage process is why patients often report strong early results from sermorelin, the first several weeks of therapy hit receptors that are fully sensitized, followed by a gradual plateau. That plateau is frequently misread as the medication losing effectiveness. In many cases, it is receptor downregulation, not peptide failure.

Why Pulsatility Is the Key Variable

The body’s natural GHRH release is not continuous. The hypothalamus fires GHRH in discrete pulses, typically every 90 to 120 minutes during sleep, with the largest pulse occurring in the first hours of deep slow-wave sleep. Between pulses, GHRH levels drop close to zero. That trough period is not wasted time, it is when GHRH receptors resensitize. Beta-arrestin dissociates, receptor phosphorylation reverses, and internalized receptors are recycled back to the somatotroph surface.

According to NIH research on pulsatile GHRH signaling and pituitary responsiveness, pulsatile GHRH delivery consistently produces greater GH secretion than continuous infusion of the same total dose over the same time period. This is not a minor difference, continuous GHRH infusion in research models has been shown to substantially blunt pituitary GH output compared to pulsed delivery, even when the cumulative dose is identical.

The clinical implication is direct: a sermorelin protocol that injects every single day without rest days is more continuous than pulsatile at the weekly level. The 5-days-on, 2-days-off model introduces a 48-hour trough that partially mimics the receptor recovery window the body relies on between natural GHRH pulses.

What the Two-Day Break Actually Accomplishes

The two rest days in a cycling protocol are not arbitrary. They serve a specific receptor-level function:

• Beta-arrestin dissociation: Within 12 to 24 hours of removing agonist stimulation, beta-arrestin begins to dissociate from internalized receptors, allowing resensitization to begin.
• Receptor recycling: Internalized GHRH receptors that were not degraded begin trafficking back to the somatotroph cell surface, partially restoring receptor density.
• Reduced GRK activity: Without ongoing agonist exposure, the kinase activity responsible for receptor phosphorylation decreases, lowering the threshold for the next activation event.

Two days is not enough time to fully restore receptor density if significant downregulation has already occurred, which is why extended pulse breaks of one to two weeks every three to four months are sometimes prescribed for patients on long-term therapy. These longer breaks allow more complete receptor recycling and new receptor synthesis to catch up.

The Practical Signal: What Desensitization Looks Like in Practice

Patients experiencing receptor desensitization typically describe one or more of the following:

• Sleep quality improvements that were noticeable in weeks one through four begin to fade by weeks six through eight
• Morning energy or recovery benefits that felt clear early in therapy become harder to attribute to the medication
• IGF-1 levels that rose appropriately in the first 90-day lab draw plateau or decline at the 180-day draw despite consistent dosing

None of these signals are definitive on their own, but a combination of subjective plateau and a flat or declining IGF-1 trend on bloodwork is a reasonable clinical indicator that dosing frequency should be reassessed, not that the dose should be increased.

Continuous Daily Dosing: When It Is and Is Not Appropriate

Continuous 7-day dosing is not categorically wrong. Some prescribers use it intentionally for patients with significantly suppressed baseline IGF-1 levels, where the clinical priority is achieving a meaningful IGF-1 response quickly before transitioning to a cycling protocol. In these cases, the patient is typically monitored with more frequent bloodwork, every 60 days rather than every 90, specifically to catch desensitization signals early.

The distinction is between using continuous dosing as a deliberate, time-limited clinical tool under active monitoring versus defaulting to it because cycling feels inconvenient. The former is a legitimate prescribing approach. The latter is where long-term outcomes tend to deteriorate.

This is also why the question of whether do you take sermorelin 7 days a week cannot be answered with a blanket yes or no. The answer depends on where you are in your treatment timeline, what your IGF-1 trend looks like, and whether your prescriber has a specific clinical rationale for the frequency they have chosen.

How to Inject Sermorelin Correctly and Safely

Sermorelin is administered by subcutaneous injection in the vast majority of clinical protocols, meaning the injection goes into the fatty tissue just beneath the skin rather than into muscle. The technique is straightforward once learned, but precision matters.

Before injecting, gather your supplies: the sermorelin vial, an insulin syringe (typically 29-31 gauge), alcohol swabs, and a sharps disposal container. Draw the correct volume as specified by your prescription, confirm there are no air bubbles, and select your injection site.

Subcutaneous vs. Intramuscular Injection: Which Is Standard?

Subcutaneous injection is the standard route for sermorelin. The injection targets the subcutaneous fat layer, most commonly in the abdomen, outer thigh, or upper arm. Intramuscular injection is occasionally used in clinical settings but is not the standard for patient self-administration. Subcutaneous delivery produces consistent absorption and is significantly more comfortable for daily or near-daily use.

The step-by-step process for subcutaneous injection:

1. Wash hands thoroughly with soap and water
2. Clean the injection site with an alcohol swab and allow to dry
3. Pinch a fold of skin between thumb and forefinger
4. Insert the needle at a 45-degree angle for thin patients, 90 degrees for patients with more subcutaneous tissue
5. Release the skin fold and slowly depress the plunger
6. Withdraw the needle smoothly and apply gentle pressure with the swab
7. Dispose of the needle immediately in a sharps container

Injection Site Rotation and Managing Missed Doses

Injection site rotation is non-negotiable for anyone on a regular sermorelin dosing schedule. Injecting the same spot repeatedly causes lipohypertrophy, a localized thickening of subcutaneous tissue that impairs absorption and creates visible lumps. Rotate between the abdomen (left and right of the navel), outer thighs, and upper arms, keeping a mental or written log if needed.

Managing missed doses is simpler than most patients expect. If you miss a scheduled dose, skip it and resume your normal schedule the following day. Do not double-dose to compensate. A single missed injection has negligible impact on IGF-1 levels or treatment outcomes. What matters is consistency over weeks and months, not perfection on any given day.

Benefits, Side Effects, and the Case for Medical Supervision

Sermorelin therapy is associated with a meaningful range of clinical benefits, but those benefits are not automatic, uniform, or permanent. They are dose-dependent, patient-specific, and contingent on a monitoring framework that most patients underestimate when they start therapy. This section covers what the benefits actually look like in practice, what side effects to watch for at each stage of treatment, and, critically, what medical supervision should concretely involve, not just why it matters in the abstract.

Reported Benefits: What Changes, When, and Why

The benefits of sermorelin therapy are mediated primarily through IGF-1, which is produced in the liver in response to growth hormone stimulation. IGF-1 acts on virtually every tissue type in the body, influencing protein synthesis, cellular repair, fat metabolism, and connective tissue maintenance. Understanding which benefits are IGF-1-driven versus directly GH-driven helps set realistic timelines.

Sleep quality (weeks 2-6): This is typically the earliest and most consistently reported benefit. Growth hormone secretion is tightly coupled to slow-wave sleep, and sermorelin’s nocturnal dosing protocol reinforces this relationship. Patients often notice deeper sleep and improved morning recovery before any body composition changes are measurable. This effect is partly direct, GH itself has sleep-modulating properties, and partly downstream through IGF-1’s role in neurological repair.

Recovery and muscle repair (weeks 4-12): IGF-1 upregulates protein synthesis in skeletal muscle and accelerates satellite cell activation, which is the mechanism behind exercise-induced muscle repair. Patients engaged in resistance training tend to notice this benefit earlier and more clearly than sedentary patients, because the anabolic signal from sermorelin requires a training stimulus to produce visible results.

Body composition changes (months 3-6): Fat metabolism improvements are among the slower-developing benefits and are frequently overstated in marketing materials. Growth hormone does stimulate lipolysis, the breakdown of stored triglycerides, but the magnitude of this effect in sermorelin therapy is modest compared to exogenous GH and is most pronounced in patients who are also managing caloric intake and exercise. Expecting significant fat loss from sermorelin alone, without lifestyle support, is a common source of patient disappointment.

Skin, connective tissue, and joint health (months 4-9): IGF-1 stimulates collagen synthesis and supports cartilage maintenance. These changes are gradual and often noticed subjectively as improved skin texture, reduced joint discomfort, or better tendon resilience during training. They are among the last benefits to appear and the first to regress if therapy is discontinued abruptly.

Side Effects by Phase: Early, Mid-Term, and Dose-Related

Side effects from sermorelin are generally mild and dose-dependent, but they are not uniform across all patients or all phases of treatment. Knowing when specific side effects are most likely to appear helps patients distinguish expected responses from signals that warrant a call to their prescriber.

Early phase (weeks 1-4):

• Injection site reactions: Redness, mild swelling, or a small raised welt at the injection site are the most common early complaints. These typically resolve within 30 to 60 minutes and diminish as the patient’s injection technique improves and site rotation becomes consistent.
• Transient flushing or warmth: Some patients notice a brief sensation of warmth or flushing shortly after injection. This is a vasodilatory response to the initial GH pulse and is generally harmless.
• Mild headache: Reported by a subset of patients in the first two to three weeks, usually resolving without intervention as the body adjusts to the new hormonal signaling pattern.

Mid-term phase (weeks 4-12):

• Water retention: As IGF-1 levels rise, some patients experience mild fluid retention, particularly in the hands and feet. This is one of the most common reasons prescribers start at conservative doses and titrate upward rather than beginning at a full therapeutic dose. Persistent or uncomfortable water retention warrants a dose review.
• Joint discomfort or stiffness: Paradoxically, the same IGF-1-driven connective tissue effects that produce long-term joint benefits can cause transient joint discomfort in the early-to-mid phase, particularly in the wrists and ankles. This is more common at higher doses and typically resolves with dose reduction.

Dose-related and less common:

• Elevated fasting glucose: Growth hormone has counter-regulatory effects on insulin, meaning high GH levels can transiently reduce insulin sensitivity. This is rarely clinically significant at standard sermorelin doses but is a meaningful consideration for patients with pre-diabetes, insulin resistance, or type 2 diabetes. Fasting glucose and HbA1c should be part of the baseline and monitoring panel for these patients.
• Elevated cortisol: Less commonly reported, but GH stimulation can influence the hypothalamic-pituitary-adrenal axis. Patients with adrenal conditions or those already managing cortisol dysregulation should discuss this with their prescriber before starting therapy.
• Antibody formation: Sermorelin, as a synthetic peptide, carries a theoretical risk of antibody development with long-term use. This was a more significant concern with earlier formulations and is considered rare with current compounded preparations, but it is a documented phenomenon and one reason long-term monitoring remains important.

What Medical Supervision Should Actually Include

The phrase ‘medical supervision is required’ appears in nearly every sermorelin article online. What almost none of them specify is what that supervision should concretely involve. This matters because the quality of oversight varies significantly between providers, and patients who understand the minimum standard of care are better positioned to evaluate whether they are receiving it.

Baseline workup before starting therapy:

• IGF-1 level (the primary efficacy marker)
• Comprehensive metabolic panel (CMP), including fasting glucose and liver function
• Lipid panel
• Complete blood count (CBC)
• For patients over 40 or with relevant history: thyroid panel, cortisol, and sex hormone panel

Baseline IGF-1 is not optional. Without it, there is no reference point against which to measure whether the therapy is working, and no way to identify if IGF-1 rises above the age-appropriate reference range, which carries its own risks.

Monitoring intervals during active therapy:

• IGF-1 recheck at 90 days from the start of therapy
• Metabolic panel at 90 days, with particular attention to fasting glucose in at-risk patients
• Follow-up IGF-1 and metabolic panel at 180 days
• Ongoing 90-day IGF-1 monitoring for patients on long-term protocols

What the prescriber should be doing with that data:

• Comparing IGF-1 to age- and sex-specific reference ranges, not just to the patient’s own baseline. An IGF-1 that has risen from 80 ng/mL to 280 ng/mL may look like a success on paper but could represent a level above the appropriate range for a 60-year-old patient.
• Adjusting dose or cycling frequency based on IGF-1 trend, not just patient-reported symptoms.
• Reviewing side effect reports in the context of dose and protocol, not dismissing them as unrelated.

The case for medical supervision is not a liability disclaimer. It is the mechanism through which sermorelin therapy produces durable, safe results rather than a short-term IGF-1 spike followed by a plateau and a set of unmanaged side effects. The difference between patients who sustain results at 12 months and those who plateau at 90 days is almost always the quality of the monitoring and adjustment process, not the starting dose.

Do You Take Sermorelin 7 Days a Week Long-Term? What the Evidence Suggests

The long-term picture for sermorelin use is still developing, as clinical trials specifically examining extended cycling protocols versus continuous daily dosing are limited. What the available evidence and clinical experience suggest is that cycling produces more durable results over treatment periods of six months or longer.

According to PubMed review of GHRH analog therapy and pituitary receptor dynamics, pulsatile administration of GHRH analogs consistently outperforms continuous infusion models in maintaining pituitary responsiveness over time. This finding aligns with the clinical preference for the 5-days-on, 2-days-off model rather than uninterrupted daily dosing.

For patients who do take sermorelin 7 days a week under medical supervision, the key variable is monitoring. IGF-1 levels should be checked regularly, and the protocol should be adjusted if levels plateau or if side effects emerge. Long-term therapy without monitoring is where outcomes deteriorate and safety risks increase.

The honest answer to whether do you take sermorelin 7 days a week long-term: some patients do, under close supervision, after establishing a stable response on a cycling protocol. It is not the starting point. It is a potential endpoint for a subset of patients whose prescribers determine the clinical benefit justifies the approach.

The real differentiator between patients who get lasting results and those who plateau is not the number of days they inject. It is whether they have a prescriber actively managing their protocol based on objective data.

---

Optimizing a sermorelin protocol requires more than a starting dose and a vague instruction to inject nightly. The decisions around cycling frequency, dose adjustments, and long-term management depend on bloodwork, clinical oversight, and a care pathway built around your specific endocrine health goals. Ascend Vitality connects patients with specialized care pathways that include medically-supported programs and prescriptions delivered directly to you, with ongoing access to providers who can adjust your protocol as your IGF-1 levels and treatment goals evolve. Get started with Ascend Vitality and take the guesswork out of hormone therapy.

Frequently Asked Questions

Is it better to take sermorelin 5 or 7 days a week?

Most prescribers start patients on a 5-days-on, 2-days-off schedule rather than daily use. The primary reason is to reduce the risk of receptor desensitization, a process where GHRH receptors on the pituitary gland become less responsive to repeated stimulation. Whether 5 or 7 days is appropriate for you depends on your IGF-1 levels, treatment goals, and your prescribing physician’s clinical judgment. Always follow your provider’s specific sermorelin dosing schedule rather than a general recommendation.

What happens if you take sermorelin every day without a break?

Taking sermorelin 7 days a week without rest days may increase the likelihood of sermorelin receptor desensitization over time. When GHRH receptors on the pituitary gland are continuously stimulated, they can downregulate, potentially reducing the effectiveness of the therapy. Some protocols do use daily dosing, particularly in the early phases of treatment, but most clinicians build in rest days to preserve long-term receptor sensitivity and maintain consistent IGF-1 levels. Your prescriber will monitor your response and adjust accordingly.

Why do some people cycle sermorelin 5 days on and 2 days off?

The sermorelin 5 days on 2 days off protocol is designed to mimic the body’s natural pulsatile release of Growth Hormone Releasing Hormone (GHRH) while giving pituitary receptors a brief recovery window. This cycling approach is thought to help prevent tolerance buildup and maintain the pituitary gland’s responsiveness to the compounded medication. It also aligns with practical patient compliance, as the two off-days are typically scheduled on weekends. Your prescriber will determine if this cycle fits your endocrine health goals.

Does sermorelin need to be taken at the same time every night?

Consistency in timing is generally recommended. Most sermorelin dosing schedules call for a subcutaneous injection in the evening, ideally before sleep, because growth hormone is naturally released in pulses during deep sleep. Taking it at a consistent time each night helps align the therapy with your body’s natural hormonal rhythm and may improve bioavailability and outcomes. If you miss a dose, do not double up the next night, simply resume your regular schedule and inform your prescribing provider.

How long does it take to see results from sermorelin therapy?

Results from sermorelin therapy are generally gradual. Many patients report early improvements in sleep quality and energy within the first few weeks. More noticeable changes in body composition, such as fat metabolism, muscle recovery, and weight management, often become apparent after two to three months of consistent use. IGF-1 levels are typically monitored via blood work at intervals your provider determines. Because sermorelin is a prescription-only compounded medication, outcomes vary based on individual health status, dosage protocol, and lifestyle factors.

Can you take sermorelin long-term?

Sermorelin therapy is sometimes used over extended periods under ongoing medical supervision. Unlike direct synthetic hormone replacement, sermorelin works by stimulating the pituitary gland to produce its own growth hormone, which some clinicians consider a more physiologically balanced approach for long-term endocrine health support. However, long-term use requires regular monitoring of IGF-1 levels, hormone panels, and clinical response. Your provider may adjust your sermorelin dosing schedule, cycle structure, or pause therapy based on your lab results and treatment progress.